NBQX, an improved non-NMDA antagonist studied in retinal ganglion cells

Brain Res. 1995 Sep 18;692(1-2):190-4. doi: 10.1016/0006-8993(95)00665-d.

Abstract

The quinoxaline derivative, 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo (F) quinoxaline (NBQX), significantly reduced the currents evoked by exogenous application of quisqualate (QQ), kainate (KA) and alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) when applied to ganglion cells, using whole-cell recording in a slice preparation of the tiger salamander retina. A comparison between NBQX and CNQX indicates that NBQX is more effective in blocking AMPA receptors. Also, at up to 10 microM, NBQX has no effect on NMDA-induced currents. Thus at this concentration, NBQX shows no affinity for the glycine binding site of NMDA receptors. For this reason, NBQX is preferred over CNQX for a more effective and selective antagonism toward non-NMDA receptors.

Publication types

  • Comparative Study

MeSH terms

  • 6-Cyano-7-nitroquinoxaline-2,3-dione / pharmacology
  • Ambystoma
  • Animals
  • Electrophysiology
  • Excitatory Amino Acid Antagonists / pharmacology*
  • In Vitro Techniques
  • Quinoxalines / pharmacology*
  • Receptors, AMPA / antagonists & inhibitors
  • Receptors, Glycine / drug effects
  • Receptors, N-Methyl-D-Aspartate / drug effects
  • Retinal Ganglion Cells / drug effects*

Substances

  • Excitatory Amino Acid Antagonists
  • Quinoxalines
  • Receptors, AMPA
  • Receptors, Glycine
  • Receptors, N-Methyl-D-Aspartate
  • 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline
  • 6-Cyano-7-nitroquinoxaline-2,3-dione